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Figure 1. Pain Circuits Converge on Limbic Regions of the Brain
Nonpeptidergic nociceptive neurons (green) project to limbic re-
gions of the brain via a multisynaptic circuit that includes neurons
within laminae II and V of the spinal cord. PKCγ+ interneurons (blue
circles) are bypassed. Peptidergic nociceptive neurons (red) com-
municate with some of the same limbic regions, via neurons in lam-
ina I and the parabrachial nucleus (Gauriau and Bernard, 2002; Jas-
min et al., 1997). Subdivisions of lamina II are indicated as IIo(outer),
IIi(inner), and IIm(middle)—a possible subdivision of IIi in the mouse
(Zylka et al., 2005). VMH, ventromedial nucleus of the hypothala-
mus; BNST, bed nucleus of the stria terminalis; Amg, amygdala.
ported to higher brain regions. Surprisingly, they found
that WGA reproducibly labeled regions with motor and
affective functions—specifically neurons in a discrete
but poorly studied region of the globus pallidus, and
limbic regions including the amygdala, ventromedial
nucleus of the hypothalamus (VMH), and bed nucleus
of the stria terminalis (BNST) (Figure 1). No other pain-
related brain regions were innervated, including the
parabrachial nucleus and the thalamus—two major tar-
gets of ascending nociceptive input from lamina I. The
absence of labeling in thalamus suggested that non-
peptidergic circuits were not important for sensory-
discriminative aspects of pain (ex. where is the pain
stimulus located, is the stimulus mechanical or ther-
mal). Instead, nonpeptidergic neurons may be more im-
portant for conveying the motivational/affective dimen-
sions of pain (ex. how unpleasant is the pain) to the
brain. It is also important to point out that, prior to this
study, the prevailing view was that lamina II did not pro-
vide substantial supraspinal projections (Gauriau and
Bernard, 2002). Clearly this is not the case. Finally, at a
technical level, it was impressive that the transgenic
approach used by Braz and colleagues was so effective
in labeling pain circuitry, up to fourth-order neurons!
The connections that Braz and colleagues observed
to affective regions of the brain are intriguing, particu-
larly when considering that peptidergic-lamina I pain
pathways also project to amygdala, VMH, and BNST
via the parabrachial nucleus (Figure 1) (Gauriau and
Bernard, 2002). This hints that there may be parallel
pain inputs to brain regions that process affect and
emotion. Admittedly, we still do not know whether
these two pain pathways converge onto the same sub-
regions (such as the central nucleus of amygdala), let
alone whether they converge onto the same neurons.
However, if these two pain pathways interact in the
brain, they could represent interlocking circuits with
feedbacks to the spinal cord. In turn, the function of
these circuits might be to maintain homeostasis by mo-
tivating behaviors that reduce an organism’s exposure
to painful stimuli (Craig, 2003). Interestingly, in a recent
paper from Caterina’s lab, it was found that P2X3
knockout mice displayed enhanced thermal avoidance
in a temperature gradient (Shimizu et al., 2005). Since
P2X3 is expressed only in nonpeptidergic neurons, and
ATP excites these neurons by opening the P2X3 ion
channel, elimination of P2X3 could change the balance
of activity within limbic regions of the brain. Altered out-
put from these limbic regions could “motivate” P2X3
mutant mice to more quickly seek out an optimal ther-
mal environment. Alternatively, ATP-sensing by non-
peptidergic neurons could regulate thermal avoidance
by a mechanism related to motor function, such as by
modulating neurons in the globus pallidus. In keeping
with this theme, pain-related activation of VMH could
gate contextually appropriate appetitive, reproductive,
or defensive behaviors (Choi et al., 2005; Gauriau and
Bernard, 2002). In affective terms, VMH activation could
motivate attraction to pleasurable stimuli or aversion
to painful sensory stimuli. Ultimately, additional genetic
and circuit-based experiments will be needed to deter-
mine precisely how these peptidergic and nonpeptider-
gic pain circuits impact somatosensory and affective
behaviors.
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Cracking Addiction the Second
Time Around: Reconsolidation
of Drug-Related Memories
One of the greatest challenges in the understanding
and treatment of addiction is cue-elicited relapse to
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773drug use. The present findings of Miller and Marshall
and Lee et al. reported in this issue of Neuron demon-
strate that retrieved drug-related memories undergo
reconsolidation and thus suggest that these maladap-
tive associations may be more labile than previously
thought.
The unremitting effects of drug abuse on brain struc-
ture and function are blamed for the inability of many
addicts to permanently abstain. Part of the difficulty in
preventing relapse is due to the persistent ability of
drug-associated environmental cues (conditioned stim-
uli, CS) to elicit drug-seeking behaviors (Robinson and
Berridge, 1993; Stewart et al., 1984). As a result, relapse
is a constant risk, despite extended periods of absti-
nence (and many decades of research). The association
of cues in the environment with subjective feelings of
pleasure that accompany appetitive behaviors (i.e., in-
gestion of palatable foods, sex, etc.) is normally highly
adaptive and ultimately enables the organism to pro-
cure such items in the future. The neurotransmitter do-
pamine plays a critical role in this process, acting as a
signal of saliency and reward and as a modulator of
memory consolidation (Routtenberg, 1979). Unfortu-
nately, nearly all drugs of abuse alter the dopaminergic
system and induce profound neuroplastic changes in
brain pathways subserving emotion and cognition.
Such changes may underlie the ability of contextual
cues to act as triggers for future drug use. Pioneering
studies using human imaging techniques (PET, MRI,
and fMRI) have provided the first glimpse into the
systems-wide effects of drugs of abuse on the brain.
These studies have shown that addicts simply viewing
drug paraphernalia or the preparation of drugs for in-
jection show marked alterations in activity in regions
involved in memory, motivation, the control of inhibi-
tory/approach behaviors, and craving (Childress et al.,
1999; Grant et al., 1996). Thus, understanding neural
plasticity in the addicted and normal brain is key to
finding a clinically efficacious treatment for this debili-
tating disease.
The nucleus accumbens, amygdala, and prefrontal
cortex, as well as their associated circuitry, all receive
strong dopaminergic inputs from the midbrain and have
been identified as prime targets of the deleterious ef-
fects of drugs of abuse (Volkow et al., 2003). Notably,
these systems are also known to contribute to the con-
solidation or the long-term stabilization of newly acquired
memories, a process requiring gene transcription and
translation. Interestingly, a retrieval phenomenon known
as reconsolidation (Misanin et al., 1968) has returned to
the spotlight in learning and memory research and in
doing so has created a fair amount of controversy. Nev-
ertheless, recent evidence indicates that some forms
of previously consolidated memories that have recently
been recalled are returned to a labile state—at least
temporarily (Dudai and Eisenberg, 2004; Lattal and
Abel, 2004; Milekic and Alberini, 2002; Nader, 2003).
Thus, in order for some recalled memories to retain the
ability to guide future behavior, additional rounds of
gene transcription and protein synthesis are necessary
to restabilize the memory, although the set of induced
genes is not necessarily identical to that utilized during
the initial consolidation process. Immediately apparent
is the prospect of using the reconsolidation period as a“second chance” to diminish the power of conditioned
stimuli over future drug-seeking behavior.
In this issue of Neuron, Miller and Marshall (2005) and
Lee et al. (2005) take advantage of the reconsolidation
phenomenon in an effort to (1) weaken the associations
formed between cocaine and the environment in which
it was experienced and (2) attenuate the probability that
a CS associated with self-administration of cocaine will
promote the learning of a novel drug-seeking response,
respectively. In doing so, both groups integrate a vari-
ety of cellular, molecular, and behavioral techniques to
advance our understanding of the molecular mecha-
nisms through which environmental cues act on the
brain as a result of addiction. These experiments are
amongst the first to demonstrate proof-of-principle for
potential reconsolidation-based therapeutic interven-
tions for drug addiction.
As alluded to above, the nucleus accumbens plays a
central role in addiction. The core subregion is involved
in the maintenance/initiation of drug-seeking behavior
(Ito et al., 2004), whereas the shell subregion mediates
the primary rewarding effects of drugs (Ikemoto et al.,
2005). Importantly, the protein extracellular signal-regu-
lated kinase 1/2 (ERK) provides a functional link be-
tween exposure to drugs of abuse and memory consol-
idation. ERK is activated in the accumbens in response
to cocaine and is part of an intracellular signaling cas-
cade that participates in memory consolidation via acti-
vation of downstream transcription factors including
Elk-1 and CREB. In fact, inhibition of the ERK kinase,
mitogen-activated protein kinase kinase (MEK), pre-
vents the establishment of a conditioned place prefer-
ence (CPP) for cocaine whereby an animal prefers an
environment previously paired with the rewarding ef-
fects of a drug relative to an unpaired environment (Val-
jent et al., 2000).
Utilizing this knowledge, Miller and Marshall first de-
monstrate by using Western blot and immunohisto-
chemistry analysis that animals displaying CPP for co-
caine show preferential activation of ERK, CREB, and
Elk-1 in the accumbens core but not the shell, an effect
which was blocked by the MEK inhibitor U1026. Inter-
estingly, animals that received intracore U1026 infu-
sions prior to testing for CPP failed to demonstrate the
behavioral response and showed no evident motoric
impairment, suggesting that the activation of the ERK
signaling pathway is necessary for “retrieval” of CPP
memory. The crux of the paper lies in the next experi-
ment, where the authors test whether activation of the
ERK pathway is required for the reconsolidation of CPP
memory. By definition, in order for reconsolidation to
occur the memory must first be retrieved. For this reason,
reconsolidation experiments always employ two post-
training test sessions; the first serves to activate re-
trieval around which experimental treatments are ad-
ministered and the second to evaluate the effect of that
manipulation on the reconsolidation process.
Here, three groups of animals were trained in the CPP
paradigm. Two days later, all groups received intra-
accumbens core U1026 infusions. The first group was
infused and returned to their homecages (no retrieval
session) in order to control for the effects of the drug
alone. The second and third groups received infusions
either pre- or post-retrieval testing, respectively. One
day later, all animals were tested for expression of CPP.
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first retrieval test would display normal CPP on the sec-
ond test day because reconsolidation is retrieval de-
pendent. Indeed, this was the case. The group that re-
ceived a post-test infusion of U1026 did not show CPP
on the second test session (an effect that was evident
even 2 weeks later), demonstrating a failure to recon-
solidate memory for the drug-paired cues. Failure to
reconsolidate was also associated with lower levels of
phosphorylated ERK, Elk-1, CREB, and Fos in the core.
Finally, rats that received pretest infusions of U1026
displayed impaired “retrieval” of the CPP memory on
the first test session, replicating their first experiment.
Surprisingly, these rats also failed to show a preference
on the second test day. This is an unexpected result
because rats with impaired retrieval should behave
similarly to rats that did not receive a retrieval session
at all. Although the authors do not comment on this
intriguing result, the data imply that the rats in the sec-
ond group probably retrieved memory for the task but
were just unable to appropriately express what they re-
trieved regardless of the mechanism. These data reem-
phasize the fact that we cannot know what an animal
has retrieved according to its ability to perform or ex-
press the output of that memory. Thus, the ERK path-
way in the accumbens core may only be needed for the
motoric expression of retrieved memories of this type.
Nevertheless, the more novel and important finding is
that the ability of what seems to be a drug-associated
contextual memory to guide behavior can be disrupted
by interfering with the reconsolidation in the accum-
bens core.
In the second paper, Lee et al. examined whether
memory for drug-associated cues is reconsolidated
within the basolateral amygdala (BLA) and, in particular,
focused on the involvement of the learning-related im-
mediately early gene/transcription factor Zif268. When
a drug state has been repeatedly paired with cues in
the environment, these cues become imbued with spe-
cific properties—as in the case above, they elicit Pav-
lovian approach and preference for the drug-paired en-
vironment. Such cues can also act as conditioned
reinforcers, such that they actually support new instru-
mental learning. In this case, the animal learns a new
response (i.e., lever pressing), reinforced solely by pre-
sentation of the previously learned cue. In other words,
the cue now has reward value and can guide or influ-
ence new behavior. It is believed that such cues exert
powerful control over the addict’s behavior, maintaining
drug seeking even in the absence of immediate rein-
forcement by the drug.
Zif268 is upregulated in the BLA following re-expo-
sure to stimuli previously paired with cocaine self-
administration (Thomas et al., 2003). Here, Lee and col-
leagues extend these finding by examining whether
Zif268 is involved in the reconsolidation of drug-related
memories. Rats were trained to self-administer cocaine
by nosepoking. Cocaine infusions were paired with the
illumination of a light. Following this training, the rats
were given one “reactivation” session in which nosep-
oking results only in the presentation of the light. Prior
to this session, rats were given an intra-amygdala injec-
tion of Zif268 antisense oligodeoxynucleotides or a
missense control infusion. The same rats were tested
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Meveral days later under new conditions (but in the
ame chamber) in which novel levers were extended
nto the chamber. Responding on the positive lever, a
esponse control animals readily learn, resulted in pre-
entation of the drug-paired cue. The authors find that
he Zif268 antisense treatment prevented animals from
ater acquiring responding with conditioned reinforce-
ent. A similar disruption in reconsolidation was found
ith intra-BLA antisense treatment in a fear condition-
ng paradigm. Thus, in the present study the authors
dvance knowledge of the molecular and anatomical
ubstrates underlying reconsolidation of drug-associ-
ted memories.
Although the implications of these experiments are
otentially quite profound, it is important to identify the
recise behavioral deficits observed after reconsolida-
ion is disrupted. For example, one can ask in the study
resented by Lee et al. whether the CS (i.e., the light
ue) retains any sort of reward value to the animal fol-
owing disruption or whether its conditioned appetitive
roperties are simply “erased”—which would be truly
xtraordinary considering the resistance of drug-CS as-
ociations to extinction. Additionally, future experi-
ents should, in addition to investigating the molecular
echanisms of reconsolidation within isolated brain re-
ions, explore the effects of altered plasticity in one
ode of a network on plasticity within the entire net-
ork involved in a particular behavior. Much data sug-
est that stimulus-drug associations formed in the
mygdala or hippocampus are integrated with a variety
f nucleus accumbens-based motor outputs (e.g., Pav-
ovian approach or exploratory drug-seeking behaviors).
herefore, does disruption of reconsolidation within the
mygdala also affect plasticity within the amygdala-
ccumbens pathway that mediates motor expression
f learned associations (and vice versa)? Indeed, the
rofile of data presented by Miller and Marshall sug-
ests that activation of the ERK pathway in the accum-
ens core could be a critical molecular link between
etrieved associations and the responses they invoke.
uestions still remain as to whether interference with
econsolidation actually diminishes the strength of the
ocaine-associated cues or the power of that associa-
ion on their ability to facilitate the learning of a new
otor response (i.e., Pavlovian to instrumental transfer).
evertheless, this set of findings suggests exciting new
venues for the treatment of addiction. While cue-elic-
ted relapse to drug use remains a daunting problem,
he unforeseen lability of recalled memories offers an
nexpected opportunity for the development of novel
nterventions.
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